Supplemental Figure 1. Adjusted fOR (points) and 95% CIs (lines) for association of individual PBDE congeners in maternal serum with time to pregnancy, according to various sensitivity analyses. (Time-to-pregnancy is censored at 13 months unless otherwise specified.)

Models:

a: Main population (N=223)

Contraceptive use & Inclusion of contraceptive failures:

b. Main + all pregnancies resulting from contraceptive failure (time-to-pregnancy=0) (N=317)

c: Main + contraceptive failure with irregular contraceptive use (time-to-pregnancy=duration of irregular use/2) (N=249)

d: Main + contraceptive failure with regular contraception use (time-to-pregnancy=0) (N=291)

e: Main + all contraceptive failure (time-to-pregnancy=0 or duration/2) (N=317)

Censoring

f: Main, censored at 7 months (N=223)

g: Main, censored at 10 months (N=223)

h: Main, censored at 15 months (N=223)

Limiting the dataset

i: Limited to primiparas (N=92)

j: Limited to those actively trying (N=107)

BDE-47


a
b
c
d
e
f
g
h
i
j
Model
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
Adjusted fOR (95% CI)

BDE-99


a
b
c
d
e
f
g
h
i
j
Model
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
Adjusted fOR (95% CI)

BDE-100


a
b
c
d
e
f
g
h
i
j
Model
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
Adjusted fOR (95% CI)

Supplemental Table 1. Association of log_{10}-transformed maternal PBDE concentration (ng/g lipid) with menstrual cycle length (in days) among women with regular menstrual cycles, CHAMACOS Study, 1999–2000 (N=191)

	Crude		**Adjusted**[b]	
Congener[a]	**β (95% CI)**	**p-value**	**β (95% CI)**	**p-value**
BDE 47	-0.5 (-1.4, 0.6)	0.40	-0.5 (-1.5, 0.6)	0.36
BDE 99	-0.6 (-1.5, 0.4)	0.24	-0.6 (-1.6, 0.3)	0.21
BDE 100	-0.5 (-1.5, 0.4)	0.28	-0.6 (-1.6, 0.4)	0.27
BDE 153	-0.8 (-1.9, 0.2)	0.11	-0.8 (-1.9, 0.2)	0.12
Sum PBDE	-0.5 (-1.5, 0.6)	0.30	-0.6 (-1.6, 0.5)	0.28

[a]log10 ng/g lipid
[b]Adjusted for age, parity and BMI